Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences.

Literature DB >> 14713404

US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences.

Abstract

Osteoporosis is a common and serious complication of glucocorticoid therapy. Recent advances in the epidemiology, pathophysiology, and management of glucocorticoid-induced osteoporosis have stimulated the development of guidelines for the prevention and treatment of this condition. In this report, the updated recommendations of the American College of Rheumatology and guidelines recently produced by the Bone and Tooth Society, National Osteoporosis Society, and Royal College of Physicians in the UK are discussed with respect to their similarities and differences.

Entities: Disease

Mesh：

Substances：
Glucocorticoids

Year: 2004 PMID： 14713404 DOI： 10.1007/s11926-004-0085-1

Source DB: PubMed Journal: Curr Rheumatol Rep ISSN： 1523-3774 Impact factor: 4.592

25 in total

1. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study.

Authors: L J Walsh; C A Wong; M Pringle; A E Tattersfield
Journal: BMJ Date: 1996-08-10

Review 2. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach.

Authors: S Amin; M P LaValley; R W Simms; D T Felson
Journal: Arthritis Rheum Date: 1999-08

3. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Authors: S Cohen; R M Levy; M Keller; E Boling; R D Emkey; M Greenwald; T M Zizic; S Wallach; K L Sewell; B P Lukert; D W Axelrod; A A Chines
Journal: Arthritis Rheum Date: 1999-11

Review 4. Use of oral corticosteroids and risk of fractures.

Authors: T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal: J Bone Miner Res Date: 2000-06 Impact factor: 6.741

5. Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study.

Authors: I Lambrinoudaki; D T Chan; C S Lau; R W Wong; S S Yeung; A W Kung
Journal: J Rheumatol Date: 2000-07 Impact factor: 4.666

6. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.

Authors: S A Khan; J A Kanis; S Vasikaran; W F Kline; B K Matuszewski; E V McCloskey; M N Beneton; B J Gertz; D G Sciberras; S D Holland; J Orgee; G M Coombes; S R Rogers; A G Porras
Journal: J Bone Miner Res Date: 1997-10 Impact factor: 6.741

7. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors: K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal: N Engl J Med Date: 1998-07-30 Impact factor: 91.245

8. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.

Authors: M Luengo; C Picado; L Del Rio; N Guañabens; J M Montserrat; J Setoain
Journal: Thorax Date: 1991-11 Impact factor: 9.139

9. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.

Authors: J Adachi; A Cranney; C H Goldsmith; W G Bensen; F Bianchi; A Cividino; G L Craig; E Kaminska; R J Sebaldt; A Papaioannou
Journal: J Rheumatol Date: 1994-10 Impact factor: 4.666

10. Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis.

Authors: A Stellon; A Davies; A Webb; R Williams
Journal: Postgrad Med J Date: 1985-09 Impact factor: 2.401

10 in total

Review 1. Guidelines for the management of osteoporosis: the present and the future.

Authors: Juliet Compston
Journal: Osteoporos Int Date: 2005-06-28 Impact factor: 4.507

2. Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study.

Authors: U Massafra; S Migliaccio; C Bancheri; F Chiacchiararelli; F Fantini; F Leoni; L S Martin; A Migliore; B Muccifora; C Napolitano; R Pastore; A Ragno; S Ronzoni; M Rotondi; M Tibaldi; P Villa; V Vinicola; E D'Erasmo; P Falaschi; G Minisola
Journal: J Endocrinol Invest Date: 2012-03-06 Impact factor: 4.256

US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences.

1. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study.

Review 2. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach.

3. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Review 4. Use of oral corticosteroids and risk of fractures.

5. Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study.

6. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.

7. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

8. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.

9. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.

10. Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis.

Review 1. Guidelines for the management of osteoporosis: the present and the future.

2. Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study.

Review 3. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.

4. Spontaneous recovery of bone mass after cure of endogenous hypercortisolism.

5. Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis.

Review 6. Glucocorticoid-induced osteoporosis: pathophysiology and therapy.

7. Role of teriparatide in treatment of glucocorticoid-induced osteoporosis.

8. Recommendations for Diagnosis and Management of Osteoporosis in COPD Men.

Review 9. Long-term therapy in COPD: any evidence of adverse effect on bone?

10. Management of glucocorticoids-induced osteoporosis: role of teriparatide.